Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Feb 20;37(6):453-460.
doi: 10.1200/JCO.18.01631. Epub 2018 Dec 7.

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

Affiliations
Free PMC article
Multicenter Study

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

Peter D Beitsch et al. J Clin Oncol. .
Free PMC article

Abstract

Purpose: An estimated 10% of breast and ovarian cancers result from hereditary causes. Current testing guidelines for germ line susceptibility genes in patients with breast carcinoma were developed to identify carriers of BRCA1/ 2 variants and have evolved in the panel-testing era. We evaluated the capability of the National Comprehensive Cancer Network (NCCN) guidelines to identify patients with breast cancer with pathogenic variants in expanded panel testing.

Methods: An institutional review board-approved multicenter prospective registry was initiated with 20 community and academic sites experienced in cancer genetic testing and counseling. Eligibility criteria included patients with a previously or newly diagnosed breast cancer who had not undergone either single- or multigene testing. Consecutive patients 18 to 90 years of age were consented and underwent an 80-gene panel test. Health Insurance Portability and Accountability Act-compliant electronic case report forms collected information on patient demographics, diagnoses, phenotypes, and test results.

Results: More than 1,000 patients were enrolled, and data records for 959 patients were analyzed; 49.95% met NCCN criteria, and 50.05% did not. Overall, 8.65% of patients had a pathogenic/likely pathogenic (P/LP) variant. Of patients who met NCCN guidelines with test results, 9.39% had a P/LP variant. Of patients who did not meet guidelines, 7.9% had a P/LP variant. The difference in positive results between these groups was not statistically significant (Fisher's exact test P = .4241).

Conclusion: Our results indicate that nearly half of patients with breast cancer with a P/LP variant with clinically actionable and/or management guidelines in development are missed by current testing guidelines. We recommend that all patients with a diagnosis of breast cancer undergo expanded panel testing.

Figures

FIG 1.
FIG 1.
Pathogenic/likely pathogenic variants identified by gene. Includes BRCA1 and BRCA2 and other genes associated with breast cancer, genes associated with breast and/or gynecologic cancers, and genes associated with other cancers. NCCN, National Comprehensive Cancer Network.

Comment in

Similar articles

See all similar articles

Cited by 19 articles

See all "Cited by" articles

References

    1. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf American Cancer Society: Breast Cancer Facts & Figures 2017-2018.
    1. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–490. - PMC - PubMed
    1. Drohan B, Roche CA, Cusack JC, Jr, et al. Hereditary breast and ovarian cancer and other hereditary syndromes: Using technology to identify carriers. Ann Surg Oncol. 2012;19:1732–1737. - PubMed
    1. Levy-Lahad E, Lahad A, King M-C. Precision medicine meets public health: Population screening for BRCA1 and BRCA2. J Natl Cancer Inst. 2014;107:420. - PubMed
    1. Childers CP, Childers KK, Maggard-Gibbons M, et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35:3800–3806. - PMC - PubMed

Publication types

MeSH terms

Substances

Feedback